Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 5Phase 1 5Phase 1/2 4Phase NA 1Phase 4 1

Status

Completed 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 152Gastrointestinal 17Tumor-Agnostic 5Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Neoplasm Metastasis 3Neoplasms 2Carcinoma 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Trastuzumab × Tumor-Agnostic × Clear all
NCT02492711 2025-03-17

SOPHIA

MacroGenics

Phase 3 Completed
624 enrolled 17 charts 1 FDA
Tumor-Agnostic

Neoplasm Metastasis

NCT03811418 2019-11-26

ATTILA

iOMEDICO AG

Phase 3 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Novartis

Phase 3 Terminated
37 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Neoplasms

NCT02721641 2017-03-31

A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer

Hoffmann-La Roche

Phase 3 Completed
69 enrolled 5 charts
Tumor-Agnostic

Neoplasms

NCT00637325 2008-03-17

TOP

Regione Lombardia

Phase 3 Unknown
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡